NVN Liquidation ( ) - 株価, ニュースと分析OTCPK:NOVN.Q

NOVN.Q 株式概要

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. 詳細

NOVN.Q ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	0/6
配当金	0/6

報酬

過去 1 年間で収益は512.7%増加しました

リスク分析

過去3か月間の株価の変動は非常に激しい

マイナスの株主資本

意味のある時価総額がありません ( $28 )

最新の財務報告は6か月以上前のものである

NVN Liquidation, Inc. 競合他社

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Baudax Bio

OTCPK:BXRX.Q

US$52.0

DMK Pharmaceuticals

OTCPK:DMKP.Q

US$10.0

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$111.0

価格と性能

の歴代最高値、変動、値下がりまとめNVN Liquidation
過去の株価
現在の株価	US$0.000001
52週高値	US$1.38
52週安値	US$0.000001
ベータ	1.65
11ヶ月の変化	-99.88%
3ヶ月変化	-99.00%
1年変化	-100.00%
33年間の変化	-100.00%
5年間の変化	-100.00%
IPOからの変化	-100.00%

Recent updates

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Jun 07

Novan Q2 2022 Earnings Preview

Aug 10

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Jul 19

株主還元

	NOVN.Q	US Pharmaceuticals	US 市場
7D	-99.9%	1.6%	2.2%
1Y	-100.0%	10.0%	31.7%

業界別リターン: NOVN.Q過去 1 年間で10 % の収益を上げたUS Pharmaceuticals業界を下回りました。

リターン対市場: NOVN.Qは、過去 1 年間で31.7 % のリターンを上げたUS市場を下回りました。

価格変動

Is NOVN.Q's price volatile compared to industry and market?
NOVN.Q volatility
NOVN.Q Average Weekly Movement	1,535.8%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

安定した株価: NOVN.Qの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: NOVN.Qの週次ボラティリティは過去 1 年間で1617%から1536%に減少しましたが、依然としてUS株の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2006	90	Scott Plesha	www.novan.com

NVN Liquidation, Inc. 基礎のまとめ

NVN Liquidation の収益と売上を時価総額と比較するとどうか。
NOVN.Q 基礎統計学
時価総額	US$28.00
収益（TTM）	-US$32.05m
売上高(TTM)	US$24.92m

0.0x

P/Sレシオ

0.0x

PER（株価収益率

NOVN.Q は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
NOVN.Q 損益計算書（TTM）
収益	US$24.92m
売上原価	US$24.45m
売上総利益	US$473.00k
その他の費用	US$32.52m
収益	-US$32.05m

直近の収益報告

Mar 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-1.14
グロス・マージン	1.90%
純利益率	-128.61%
有利子負債／自己資本比率	-1,164.1%

NOVN.Q の長期的なパフォーマンスは？

過去の実績と比較を見る

NOVN.Q 株式概要

報酬

リスク分析

NVN Liquidation, Inc. 競合他社

OTCPK:PLXP.Q

US$30.0

OTCPK:BXRX.Q

US$52.0

OTCPK:DMKP.Q

US$10.0

OTCPK:RVLP.Q

US$111.0

価格と性能

最新ニュース

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Price target decreased by 12% to US$11.50

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Price target decreased by 12% to US$11.50

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 14% to US$11.50

Consensus EPS estimates fall by 16%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 13% to US$12.67

Forecast to breakeven in 2025

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novan Q2 2022 Earnings Preview

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $40.000004 million.

Novan shares under pressure after proposing capital raise

Novan, Inc. Reports Positive Topline Results from Pivotal Phase 3 Trial of Sb206 in Patients with Molluscum Contagiosum

Novan, Inc. Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

Novan, Inc. Announces Results from Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan’s NVN4100 shows antimicrobial effect against bacteria in animal health

Novan, Inc. Announces Final Week-12 Visit for Last Patient in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Contemplates Bankruptcy

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

Novan regains Nasdaq compliance for minimum bid price requirement

Novan Updates Enrollment for Its B-SIMPLE4 Pivotal Phase 3 Study Evaluating SB206

Novan Exceeds 60% Enrollment in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan Receives Approval from the Listing Qualifications Department of the Nasdaq Stock Market

Novan EPS in-line, beats on revenue

Novan, Inc. Announces Positive in vitro Results Showing the Potential Efficacy of Its NITRICIL™ Platform Technology as an Antiviral Against SARS-CoV-2 the Virus That Causes COVID-19

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Novan, Inc. May File for Bankruptcy

Earnings released

Price target lowered to US$2.75

Novan, Inc.(NasdaqGM:NOVN) dropped from Russell Microcap Value Index

株主還元

価格変動

会社概要

NVN Liquidation, Inc. 基礎のまとめ

0.0x

0.0x

収益と収入